Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Cancer Prev Res (Phila). 2008 Aug;1(3):208–214. doi: 10.1158/1940-6207.CAPR-08-0021

Fig. 2. Celecoxib and LGD1069 suppress mammary aromatase activity.

Fig. 2

Aromatase activity was measured in mammary glands harvested from mice from each of the four experimental groups in the experiment shown in Fig. 1 (Study II). Aromatase activity in all three drug-treated groups was significantly lower than that in the control group (*; P<0.001). Celecoxib caused a modest reduction in mammary aromatase activity (83% of control). Aromatase activity was decreased to 71% in tissues from mice treated with LGD1069 alone, and to 44% in tissues from mice treated with both celecoxib and LGD1069. Aromatase activity in tissues from the celecoxib/LGD1069 combination group was significantly less than that in samples from animals treated with LGD1069 alone (‡, P<0.001). Enzyme activity is expressed as fmol/μg protein/h. Data shown are mean + SD, n=6 per group.